Annals of Clinical Epidemiology
Online ISSN : 2434-4338
最新号
選択された号の論文の4件中1~4を表示しています
STUDY PROTOCOL
  • Jun Morinaga, Sayaka Shimizu, Yoshikazu Miyasato, Eiji Matsunaga, Hiro ...
    原稿種別: STUDY PROTOCOL
    2026 年8 巻4 号 p. 107-114
    発行日: 2026/10/01
    公開日: 2026/10/01
    [早期公開] 公開日: 2025/12/05
    ジャーナル オープンアクセス HTML

    BACKGROUND

    The incidence of end-stage kidney disease (ESKD) caused by chronic kidney disease is increasing worldwide. Patients with ESKD often exhibit significant premature aging and have a higher risk of premature mortality than the general population. Here, we conducted a prospective cohort study, the Kumamoto Hemodialysis Cohort Study, to explore the mechanisms of the premature aging phenotype exhibited by these patients using biological markers and highly detailed clinical information in a real-world setting.

    METHODS

    This multicenter prospective cohort study targeted adult outpatients receiving maintenance hemodialysis therapy in Kumamoto Prefecture, Japan. After enrollment, the patients were followed up for 10 years. Data were collected from the electronic medical records of medical facilities that participated retrospectively and prospectively from January 1, 2017. Clinical information was collected from electronic medical records, medical chart reviews, and patient-completed questionnaires. Serum and plasma samples were collected every 3 years. Thus far, 1,241 patients have been enrolled in this study, and we found the median age of the participants was 69 years, and 67.5% were male. Among the primary causes of kidney failure, diabetic nephropathy accounted for 38.6% of all cases, followed by glomerulonephritis (27.2%) and nephrosclerosis (9.9%). The median hemodialysis vintage was 5.8 years.

    CONCLUSION

    This study contributes to the characterization of a premature aging phenotype together with morbidity and mortality of patients with ESKD, thereby providing insights into the prevention of the onset of premature aging-related diseases in patients receiving maintenance hemodialysis therapy.

SEMINAR
  • Atsushi Miyawaki, John N. Mafi, A. Mark Fendrick, Yusuke Tsugawa
    原稿種別: SEMINAR
    2026 年8 巻4 号 p. 115-126
    発行日: 2026/10/01
    公開日: 2026/10/01
    [早期公開] 公開日: 2025/12/05
    ジャーナル オープンアクセス HTML

    This narrative review summarizes the concepts of low- and no-value care (LNVC), the drivers behind them, and potential strategies for de-implementation, all with a particular focus on influential conceptual and empirical research. Low-value care (LVC) refers to healthcare services for which the costs outweigh the potential benefits, while no-value care (NVC) is a narrower definition that refers to healthcare services that provide no net clinical benefit for patients (regardless of the costs). A growing global body of research shows that LNVC is widespread and imposes substantial societal costs. Mitigating the provision of such care would reduce avoidable healthcare expenditures, improve the quality and safety of treatment by minimizing overdiagnosis and overtreatment, and improve overall health by reallocating resources to high-value care. LNVC arises from interrelated factors at the system, individual-provider, and consumer-demand levels, including system incentives, industry promotion, patient expectations, and physicians’ knowledge, habits, and fears. Despite increasingly intense efforts to address LNVC, several challenges persist in terms of identification, measurement, and intervention. Multicomponent interventions targeting healthcare providers have been shown to be effective at reducing LNVC from the supply side; such interventions may include recommendations from professional societies, quality metrics for LNVC, quality-improvement initiatives, clinical decision-support tools, and payment reforms (e.g., global budgets, prior authorizations, coverage policy). Given the uneven provision of LNVC, targeted strategies centered on high-volume providers could improve the efficiency of interventions. Importantly, eliminating NVC represents a clear and actionable starting point to facilitate coordinated, multi-level efforts and collaboration among a diverse range of stakeholders.

ORIGINAL ARTICLE
  • Koichi Sakakibara, Daisuke Shigemi, Rena Toriumi, Nobuaki Michihata, H ...
    原稿種別: ORIGINAL ARTICLE
    2026 年8 巻4 号 p. 127-134
    発行日: 2026/10/01
    公開日: 2026/10/01
    [早期公開] 公開日: 2025/12/24
    ジャーナル オープンアクセス HTML

    BACKGROUND

    This study retrospectively evaluated the user experience and safety outcomes of medical chatbot service providing medicine use information to pregnant and lactating women.

    METHODS

    The chatbot utilized in this study did not employ generative artificial intelligence (such as large language models). Rather, it was a rule-based system in which all response patterns were predefined. We collected user survey data between December 13, 2021, and August 10, 2022. User status, satisfaction, addressed consultation categories, and post-use health problems were analyzed.

    RESULTS

    The study included 1,000 records, comprising 419 (41.9%) cases of pregnant women and 581 (58.1%) cases of lactating women across Japan. The overall satisfaction was 93.9%, with no significant difference between pregnant and lactating women (P = .866). Headache was the most frequently consulted category followed by cold symptoms and hay fever symptoms. High satisfaction levels were observed across the consultation categories. None of the participants indicated post-use health problems.

    CONCLUSION

    A medical chatbot service providing medicine use information to women during pregnancy and lactation can achieve high satisfaction and safety.

SHORT REPORT
feedback
Top